

What is claimed is:

1. Use of a pharmaceutical composition in the manufacture of a medicament for treating a vascular eye disease or disorder in a subject, the composition, comprising:

(i) aflibercept; and

(ii) nesvacumab.

2. The use of claim 1, wherein the aflibercept is present in an amount of 40 mg/mL, and the nesvacumab is present in an amount of from 10 mg/ml to 120 mg/ml.

3. The use of any one of claims 1 or 2 wherein the eye disease or disorder is selected from the group consisting of diabetic retinopathy, diabetic macular edema, age-related macular degeneration, retinal neovascularization, central retinal vein occlusion, branched retinal vein occlusion, polypoidal choroidal vasculopathy, choroidal neovascularization, retinal angiogenesis, and vascular leak.

4. The use of claim 3 wherein one or more doses of the pharmaceutical composition once every 9 weeks are administered to the subject.

5. The use of claim 3, wherein an initial dose followed by one or more secondary doses administered 1 to 4 weeks after the immediately preceding dose followed by one more tertiary doses administered 5 to 12 weeks after the immediately preceding dose of the pharmaceutical composition are administered to the subject.

6. The use of claim 5, wherein at least 2 secondary doses of the pharmaceutical composition are administered to the subject.

7. The use of claim 1, wherein the pharmaceutical composition further comprises:

(i) a buffer at pH of 6.2 ± 0.3 ;

(ii) a non-ionic detergent;

(iii) a tonicity agent; and

(iv) a stabilizer.

8. The use of claim 7, wherein:

(a) the buffer is sodium phosphate;

(b) the sodium phosphate concentration is $10 \text{ mM} \pm 1.5 \text{ mM}$;

(c) the non-ionic detergent is polysorbate 20;

(d) the polysorbate 20 concentration is $0.03\% \text{ w/v} \pm 0.0045\%$;

(e) the tonicity agent is sodium chloride;

(f) the sodium chloride concentration is $40 \text{ mM} \pm 6.0 \text{ mM}$;

(g) the stabilizer is sucrose; and

(h) the sucrose concentration is $5\% \pm 0.75\%$.